The interplay between bicarbonate kinetics and gastrointestinal upset on ergogenic potential after sodium bicarbonate intake: a randomized double-blind placebo-controlled trial

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11510%2F23%3A10464660" target="_blank" >RIV/00216208:11510/23:10464660 - isvavai.cz</a>

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=avovups8ta" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=avovups8ta</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1038/s41598-023-34343-0" target="_blank" >10.1038/s41598-023-34343-0</a>

Jazyk výsledku

angličtina

Název v původním jazyce

The interplay between bicarbonate kinetics and gastrointestinal upset on ergogenic potential after sodium bicarbonate intake: a randomized double-blind placebo-controlled trial

Popis výsledku v původním jazyce

This double-blind placebo-controlled cross-over study utilized comprehensive monitoring of blood bicarbonate (HCO3-) kinetics and evaluation of gastrointestinal (GI) upset to determine their impact on an ergogenic potential of sodium bicarbonate (SB) co-ingested with carbohydrate (CHO). Nineteen CrossFit athletes performed 6 bouts of 15 s Wingate Anaerobic Test (WAnT) 90 min post-ingestion of 0.4 g.kg-1 body mass (BM) of SB (SB+CHO treatment) or PLA (PLA+CHO treatment) with 15 g CHO. Blood HCO3- concentration was evaluated at baseline, 30-, 60-, 75- and 90 min post-ingestion, in between WAnT bouts, and 3 and 45 min post-exercise, while GI upset at 120 min after protocol started. Control (no supplementation; CTRL) procedures were also performed. An efective elevation of extra-cellular bufering capacity was observed 60-90 min post-ingestion of SB+CHO. At mean peakblood HCO3-, or at start of exercise an increase&gt; 6 mmol.L-1 in HCO3- was noted in 84% and 52.6% participants, respectively. SB+CHO did not prevent performance decrements in WAnT bouts. There were no signifcant relationships between changes in blood HCO3- and WAnTs&apos; performance. Total GI was signifcantly higher in SB+CHO compared to CTRL, and stomach problems in SB+CHO compared to CTRL and PLA+CHO. There were inverse associations between peak- (p = 0.031; r = - 0.495), average- (p = 0.002; r = - 0.674) and minimum power (p = 0.008; r = - 0.585) and total GI upset, as well as average power and severe GI distress (p= 0.042; r = - 0.471) at SB+CHO. The implemented dose of SB+CHO was efective in improving bufering capacity, but did not prevent decrements in WAnTs&apos; performance. GI side efects were crucial in afecting the ergogenic potential of SB and thus must be insightfully monitored in future studies.

Název v anglickém jazyce

The interplay between bicarbonate kinetics and gastrointestinal upset on ergogenic potential after sodium bicarbonate intake: a randomized double-blind placebo-controlled trial

Popis výsledku anglicky

This double-blind placebo-controlled cross-over study utilized comprehensive monitoring of blood bicarbonate (HCO3-) kinetics and evaluation of gastrointestinal (GI) upset to determine their impact on an ergogenic potential of sodium bicarbonate (SB) co-ingested with carbohydrate (CHO). Nineteen CrossFit athletes performed 6 bouts of 15 s Wingate Anaerobic Test (WAnT) 90 min post-ingestion of 0.4 g.kg-1 body mass (BM) of SB (SB+CHO treatment) or PLA (PLA+CHO treatment) with 15 g CHO. Blood HCO3- concentration was evaluated at baseline, 30-, 60-, 75- and 90 min post-ingestion, in between WAnT bouts, and 3 and 45 min post-exercise, while GI upset at 120 min after protocol started. Control (no supplementation; CTRL) procedures were also performed. An efective elevation of extra-cellular bufering capacity was observed 60-90 min post-ingestion of SB+CHO. At mean peakblood HCO3-, or at start of exercise an increase&gt; 6 mmol.L-1 in HCO3- was noted in 84% and 52.6% participants, respectively. SB+CHO did not prevent performance decrements in WAnT bouts. There were no signifcant relationships between changes in blood HCO3- and WAnTs&apos; performance. Total GI was signifcantly higher in SB+CHO compared to CTRL, and stomach problems in SB+CHO compared to CTRL and PLA+CHO. There were inverse associations between peak- (p = 0.031; r = - 0.495), average- (p = 0.002; r = - 0.674) and minimum power (p = 0.008; r = - 0.585) and total GI upset, as well as average power and severe GI distress (p= 0.042; r = - 0.471) at SB+CHO. The implemented dose of SB+CHO was efective in improving bufering capacity, but did not prevent decrements in WAnTs&apos; performance. GI side efects were crucial in afecting the ergogenic potential of SB and thus must be insightfully monitored in future studies.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30306 - Sport and fitness sciences

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2023

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Scientific Reports

ISSN

2045-2322

e-ISSN

2045-2322

Svazek periodika

13

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

14

Strana od-do

1-14

Kód UT WoS článku

000984749800003

EID výsledku v databázi Scopus

2-s2.0-85158039926